XBIOHealthcare · BiotechnologyXBIO Stock Forecast: Xenetic Biosciences, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half.
XBIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Xenetic Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Value (10): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Xenetic Biosciences, Inc. — and when they’d sell — is the membership.
XBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 May 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 11 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 2 May 2022 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 11 Jan 2021 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $5.00 |
| 25 Nov 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 20 Dec 2016 | Ladenburg Thalmann | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
XBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Xenetic Biosciences, Inc. (XBIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.6×
- Price / sales
- 1.8×
- Price / book
- 0.8×
- EV / EBITDA
- 0.5×
Cheaper than 84% of US stocks
Cheaper than 55% of US stocks
Cheaper than 78% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- 36.0%
- Earnings growth (YoY)
- 36.0%
- Gross margin
- —
- Operating margin
- −62.2%
- Net margin
- −70.0%
Higher than 82% of US stocks
Higher than 72% of US stocks
Higher than 16% of US stocks
Higher than 8% of US stocks
- Return on equity
- −37.0%
- Return on assets
- −21.8%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
XBIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XBIO appears on the weeks it earns a place.
Frequently asked questions about XBIO stock
Is XBIO stock a buy right now?
Of the 1 analysts covering Xenetic Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenetic Biosciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank XBIO?
As at 1 Aug 2026, Xenetic Biosciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
What is the XBIO stock forecast for 2030?
No analyst covering Xenetic Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIO are extrapolating price history, which says nothing about the business.
How has XBIO stock performed over the past year?
Xenetic Biosciences, Inc. returned -17.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing novel therapies for life-threatening diseases.
About Xenetic Biosciences, Inc.
Xenetic Biosciences Inc. is a biopharmaceutical company that focuses on developing novel therapies for life-threatening diseases. Its primary function is the advancement of next-generation biologics by leveraging its innovative and proprietary drug delivery platform technology called PolyXen™. This platform is designed to extend the efficacy and improve the pharmacokinetics of biologic drugs. With a strong emphasis on oncology, Xenetic Biosciences is at the forefront of creating novel therapeutics with the potential to significantly impact the healthcare industry. The company is involved in research and development, aiming to produce targeted therapies that can enhance the standard of care in unmet medical needs. It engages with strategic collaborations and partnerships to spearhead its development programs, maximizing the potential for clinical success. Xenetic Biosciences plays a vital role in the biopharmaceutical sector by contributing to scientific advancements and addressing critical medical challenges. Headquartered in Framingham, Massachusetts, this company represents a key player in the ongoing pursuit of effective and innovative medical treatments.
CEO Mr. James F. Parslow · 2 employees · United States · https://www.xeneticbio.com